Shanghai INT medical instruments reports interim revenue growth despite margin dip

Shanghai INT Medical Instruments Co. Ltd. reported a 17.52% increase in revenue to RMB461.08 million for the six-month period ended June 30, 2025, up from RMB392.32 million in the prior year. This growth was primarily fueled by a 13.57% rise in sales of interventional medical devices to RMB392.37 million and a substantial 118.69% increase in agent business revenue to RMB32.41 million. Gross profit for the period grew by 9.68% to RMB270.66 million, though the gross profit margin decreased from 62.90% to 58.70%, attributed to the higher proportion of lower-margin agent business sales.

Profit for the period saw a modest increase of 3.29% to RMB102.44 million, compared to RMB99.18 million in 2024. Basic and diluted earnings per share were RMB0.57, a slight decrease from RMB0.58 in the previous year. The company's income tax expenses rose by 57.91% to RMB18.27 million, with an effective tax rate of 15.14%.

As of June 30, 2025, current assets totaled RMB869.34 million against current liabilities of RMB695.54 million, resulting in a current ratio of 1.25. The gearing ratio increased to 29.08% due to higher bank loans. The board did not recommend an interim dividend for the period.